RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers.
Li XiaEnming TianMingcheng YuChenglong LiuLian ShenYafei HuangZhongen WuJinlong TianKer YuYonghui WangQiong XieDi ZhuPublished in: Journal of experimental & clinical cancer research : CR (2022)
T cell tumor infiltration. Our findings provide the mechanistic insights implicating the RORγt agonist in immunotherapy and offer a strategy for targeting the RORγt agonist to improve PD-1 antibody efficacy in cancers.